US Patent

US11077055 — Orally disintegrating compositions

Formulation · Assigned to Dexcel Pharma Technologies Ltd · Expires 2036-04-21 · 10y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an orally disintegrating dosage form of a proton pump inhibitor, such as Prevacid, that rapidly disintegrates in the oral cavity after administration.

USPTO Abstract

An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.

Drugs covered by this patent

Patent Metadata

Patent number
US11077055
Jurisdiction
US
Classification
Formulation
Expires
2036-04-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Dexcel Pharma Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.